WO1995011238A1 - Heterocyclic amines for treating ischaemic strokes - Google Patents

Heterocyclic amines for treating ischaemic strokes Download PDF

Info

Publication number
WO1995011238A1
WO1995011238A1 PCT/EP1994/003425 EP9403425W WO9511238A1 WO 1995011238 A1 WO1995011238 A1 WO 1995011238A1 EP 9403425 W EP9403425 W EP 9403425W WO 9511238 A1 WO9511238 A1 WO 9511238A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alk
heptyl
group
Prior art date
Application number
PCT/EP1994/003425
Other languages
French (fr)
Inventor
David Gwyn Cooper
Ronald Joseph King
Thomas Henry Brown
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP94929558A priority Critical patent/EP0724577A1/en
Priority to JP7511321A priority patent/JPH09504016A/en
Priority to AU78566/94A priority patent/AU7856694A/en
Publication of WO1995011238A1 publication Critical patent/WO1995011238A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • the present invention relates to amine derivatives, more particularly aryloxy-, arylthio- or aroyl-alkylamino compounds, to processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of ischaemic stroke.
  • Stroke is reportedly the third most common cause of death in the developed world.
  • Current therapies for ischaemic stroke are limited and have a number of disadvantages, such as the risk of exacerbating haemorrhage. There is therefore a need for new and improved treatments for ischaemic stroke.
  • EP- A- 103252 discloses a broad class of aryloxyalkylamino derivatives. These compounds are said to have utility as herbicides.
  • French Patent Application No. 1601591 describes a class of nitrogen-containing heterocyclic compounds derived from phenoxyalkyl alcohols, which are said to be cholesterol-lowering agents.
  • British Patent No. 924961 describes, as intermediates for the preparation of anti- nematodal agents, compounds of formula R.W.CH2.CH2.NXY, wherein R is phenyl optionally substituted by inter alia halogen, alkyl or alkoxy, X and Y are inter alia alkyl, or NXY represents a pyrrolidino, piperidino or morpholino group and W is a straight saturated chain containing up to 16 carbon atoms and 1 to 3 non-adjacent oxygen atoms.
  • the present invention therefore provides, in a first aspect, the use of a compound of formula (I):
  • n is preferably from 5 to 9, most preferably 7.
  • Alk 1 and Alk 2 preferably independently represent CH2 or when branched, C(H)(CH3) or C(CH3)2-
  • a is oxygen q is preferably zero and p is preferably zero or 1.
  • p + q is preferably 1 or 2.
  • p and q are preferably both zero.
  • tricyclic heteroaryl groups Ar include dibenzofuranyl, dibenzothienyl, carbazole, N-methylcarbazole, acridine and dibenzoxepine.
  • the tricyclic moiety can be linked to the remainder of formula (I) via any suitable ring atom.
  • Suitable substituents for Ph, and tricyclic heteroaryl groups include, for example, 1 to 3 substituents selected from halogen, trifluoro methyl, trifluoromethoxy, C ⁇ 4alkyl and C ⁇ 4alkoxy.
  • Ar is phenyl mono-substituted by a halogen atom or by a group selected from phenoxy, benzoyl, halobenzoyl or benzyl or benzyloxy in which the -CH2- moiety may optionally be substituted by one or two methyl groups; or Ar is phenyl disubstituted by a halogen atom; or Ar is 2-dibenzofuranyl.
  • Ar is phenyl substituted by benzyl, benzoyl, fluorobenzoyl, chlorobenzoyl or benzyloxy.
  • the substituent is preferably at the 3- or 4- position of the phenyl ring.
  • Alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched.
  • a C ⁇ galkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as isopropyl, t-butyl, or sec-pentyl.
  • a salt of a compound (I) should be pharmaceutically acceptable.
  • pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other non- pharmaceutically acceptable salts may be used for example in the isolation of a final product and are included within the scope of this invention.
  • the compounds of formula (I) may contain one or more asymmetric centres. Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. Certain compounds of formula (I) are believed to be novel. Thus, in a further aspect the invention provides novel compounds of formula (IA):
  • R 1 , R 2 , n and Ar are as defined for formula (I); and salts thereof.
  • the invention also provides a compound of formula (IB) : Formula (IB) and salts thereof, wherein R 1 , R 2 , and X are as defined for formula (I) and Ar 1 represents phenyl optionally substituted by a group Ph(Alk 1 )pA(Alk 2 )q- or a tricyclic heteroaryl group as defined for formula (I), provided that when X is O or S, and NR- ⁇ R 2 represents a heterocyclic ring which does not contain an optional further heteroatom then Ar 1 is phenyl substituted by a group Ph(Alk 1 )pC(O)(Alk 2 )q-.
  • Particular compounds of the invention which are believed to be novel compounds include: N-[7-(4-benzyloxyphenoxy)heptyl]-N-methylcyclohexylamine,
  • the compounds of the present invention can be prepared by processes analogous to those known in the art.
  • the present invention therefore provides in a further aspect, a process for the preparation of a novel compound of formula (I) which comprises: (a) to prepare a compound wherein X represents O or S reaction of a compound of formula (II):
  • reaction between a compound of formula (II) and a compound of formula (IH) can be carried out under standard conditions.
  • L 1 is hydroxy
  • the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
  • Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
  • This reaction may optionally be effected in the presence of a solvent such as tetrahydrofuran.
  • the leaving group L 1 may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy.
  • the reaction may be effected in the absence or presence of solvent such as dimethylformamide or methylethylketone in the presence of a base such as sodium hydride or potassium carbonate and at a temperature in the range 0 to 200°C.
  • the reaction of a compound of formula (IV) with a compound of formula (V) according to process (b) may be effected in conventional manner, for example using excess amine as solvent or alternatively using an organic solvent, e.g. an alcohol such as methanol or ethanol; dimethylformamide, or chloroform.
  • the leaving group L 2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p- toluenesulphonyloxy.
  • reaction may be carried out in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide or an excess of the amine (V) may be employed.
  • a base such as potassium carbonate, sodium hydride or potassium t-butoxide
  • reductive amination of an aldehyde (Vl ⁇ ) may be effected using a reducing agent such as sodium cyanoborohydride in the presence of a compound of formula (V), according to procedures well known in the art.
  • a reducing agent such as sodium cyanoborohydride
  • reaction of compounds (EX) and (X) may be effected in an analogous manner to process (a) described above.
  • Reduction of a pyridinium derivative (XI) according to process (f) may be effected for example by hydrogenation, using a noble metal catalyst such as palladium on charcoal, platinum or platinum oxide (Adam's catalyst), suitably in a solvent such as an alcohol e.g. ethanol.
  • a noble metal catalyst such as palladium on charcoal, platinum or platinum oxide (Adam's catalyst)
  • a solvent such as an alcohol e.g. ethanol.
  • reaction between a compound of formula (XII) and a compound F-Ar is preferably effected in the presence of a strong base such as sodium hydride, and in a polar organic solvent such as dimethylsulphoxide or dimethylformamide.
  • Interconversion reactions according to process (h) may be carried out using standard methods.
  • a compound of formula (II) can be prepared under standard alkylation conditions by reacting a compound of formula (XIII) :
  • L 1 and L 2 are preferably selected so that the compound of formula (V) reacts selectively with L 2 .
  • L 1 is suitably hydroxy and L 2 is suitably halo.
  • Compounds of formula (IV) can be prepared by reacting a compound of formula (HI) as hereinbefore defined with a compound of formula (XIII) as hereinbefore defined.
  • L and L 2 can be identical, for example halo.
  • the reaction is suitably carried out in the presence of a weak base such as potassium carbonate.
  • the reaction may be carried out under phase transfer conditions using a strong base such as potassium hydroxide.
  • a compound of formula (TV) may be prepared by Friedel-Craft acylation of a compound HAr with an acylating agent of the formula L 2 (CH2) n C(O)Hal, where Hal represents a halogen atom such as bromo or chloro.
  • the carbonyl group in the resulting compound of formula (IV) may if desired subsequently be reduced.
  • Compounds of formula (VII) may be prepared by acylation of a compound of formula (V) for example with an appropriate acid chloride or ester, which may itself be prepared from a compound of formula (IE) by reaction with an appropriate, commercially available bromoalkyl ester or acid, followed if necessary or desired by conversion to an acid chloride.
  • a compound (VII) may be prepared by a method analogous to process (a).
  • An aldehyde of formula (VI-O) may be prepared for example by reduction of the corresponding nitrile using a reducing agent such as diisobutyl aluminium hydride, in the presence of an inert solvent such as toluene.
  • reductive animation of the aldehyde is carried out in situ, i.e. the compound of formula (I) is obtained from the nitrile in a one-pot reaction without isolation of the intermediate aldehyde.
  • the nitrile may itself be prepared by reacting a compound of formula (IV) wherein L 2 is halo with potassium cyanide.
  • Compounds (VTfl) may also be prepared by other standard procedures such as reduction of an ester or oxidation of an alcohol.
  • Compounds of formula (IX) may be prepared by methods analogous to any of processes (a) - (d) described herein. Alternatively a compound (IX) may be obtained by catalytic hydrogenation of a corresponding compound of formula (I) wherein Ar represents a benzyloxyphenyl group. This therefore provides a further method of converting a compound of formula (I) to a different compound of formula (I).
  • Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, t- butoxycarbonyl or benzyloxycarbonyl.
  • An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
  • a compound of formula (I) When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
  • the invention also encompasses any novel intermediates described herein, in particular those of formulae (II), (IV), (VI), (VII), (IX) and (XI).
  • Compounds of the invention have been found to exhibit high calcium influx blocking activity, for example in neurons.
  • the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans.
  • the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal.
  • the invention also provides a method of treatment of conditions or diseases related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a novel compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient
  • the compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. Parenteral administration is generally preferred.
  • the compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid ca ⁇ ier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid ca ⁇ ier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be.
  • any suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as cyclodextrins.
  • composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400 mg per day.
  • the total daily dosage by oral administration could be in the range 1 to 2000 mg and the total daily dosage by parenteral administration could be in the range 0.1 to 400 mg.
  • the compounds may be administered for a period of continuous therapy, for example for a week or more.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator; an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor.
  • a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator
  • an excitatory amino acid antagonist such as an NMDA antagonists
  • a free radical inhibitor such as an NMDA antagonists
  • a calpain inhibitor a compound of formula (I) or a pharmaceutically acceptable salt thereof
  • the pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl2, 4; ATP, 2; buffered to pH 7.2 with CsOH.
  • Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca 2+ currents.
  • the external solution for recording Ca + channel currents contained in mM: BaCl2, 10; TEA-C1, 130; glucose, 10; HEPES, 10; MgCl2, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided.
  • Ca-2 + currents Peak voltage gated Ca + channel cunrents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba 2+ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow rundown of current as is commonly seen when recording Ca + currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a rundown corrected control value. Dorsal Root Ganglion Cells
  • Buffer Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
  • Solvent Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
  • Diluent e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
  • Disintegrant e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
  • Suspending agent e.g. Xanthan gum, microcrystalline cellulose
  • Diluent e.g. sorbitol solution, typically water
  • Preservative e.g. sodium benzoate
  • Buffer e.g. citrate
  • Co-solvent e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
  • 1,7-Dibromoheptane (12.9g) was added dropwise to a stirred solution of 4- benzyloxyphenol (lOg), sodium hydroxide (2.5g), benzyltriethylammonium chloride (0.4g) and water (30ml). The mixture was stirred at 50°C for 18 hours, water (50ml) added and the solution extracted with dichloromethane (2 x 100ml). The combined dichloromethane extracts were dried over magnesium sulphate, solvent was removed and the residue was chromatographed on silica gel eluted with hexane/dichloromethane to give the title compound (4.25g) as a solid, m.p. 56 - 59°C.
  • Example 1 N-[7-(4-Benzyloxyphenoxy)heptyl]-N-methylcyclohexylamine hydrochloride A mixture of 7-(4-benzyloxyphenoxy)-l-bromoheptane (1.88g), 80% sodium hydride (0.17g) and dimethylformamide (10ml) was stirred under nitrogen for 5 minutes. N- methylcyclohexylamine (0.65ml) was added by syringe and the mixture was stirred at 60°C for 4 hours. The solvent was removed and the residue treated with water and extracted with ether.
  • N-[7-(4-Benzyloxyphenoxy)heptyl]dimethylamine hydrochloride The title compound was prepared in a similar manner to Example 2 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.25g), 33% dimethylamine in ethanol (10ml) and chloroform (50ml). Treatment with ethereal hydrogen chloride and recrystallisation from acetonitrile gave the title compound as a white solid, (0.638g), m.p. 152 - 153°C.
  • the title compound was prepared in a similar manner to Example 1 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.88g), 80% sodium hydride (0.17g), N- methylpiperazine (0.55ml) and dimethylformamide (10ml). Treatment with ethereal hydrogen chloride and recrystallisation from ethanol gave the title compound as a white solid, (0.93g), m.p. 238 - 241 °C.
  • Example 13 l- ⁇ 7-[4-(4-Chlorobenzoyl)phenoxy]heptyl ⁇ piperidine hydrochloride
  • a solution of 7-piperidinoheptanol (l.Og), 4-chloro-4'-hydroxybenzophenone (1.16g), triphenylphosphine (1.31g) in tetrahydrofuran (20ml) was treated with diethyl azodicarboxylate (0.87g).
  • the resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with 10% methanol in chloroform.
  • the resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride.
  • (+)-l- ⁇ 7-[4-(l-Phenylethyloxy]phenoxy]heptyl ⁇ piperidine hydrochloride A solution of 7-(4-hydroxyphenoxy)-l-piperidinoheptane (WO93/22302; 0.75g), ( ⁇ )-l- phenylethanol (0.3 lg), triphenylphosphine (0.61g) in tetrahydrofuran (20ml) was treated with diethyl azodicarboxylate (0.44g). The resulting solution was sti ⁇ ed at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with 10% methanol in chloroform.
  • the title compound was prepared in a similar manner to Example 15 starting from 1- bromo-8-[4-(4-fluorophenoxy)phenyl]-8-oxyoctane (2.0g) and using corresponding molar amounts of the other reagents. Treatment with ethereal hydrogen chloride and crystallisation under ether gave the tide compound as a white solid, (1.53g), m.p. 111 - 112°C.
  • the title compound was prepared in a similar manner to Example 15 starting from 1- bromo-6-(4-phenoxy)phenyl-6-oxyhexane (1.5g) and using corresponding molar amounts of the other reagents. Treatment with ethereal hydrogen chloride and crystallisation under ether gave the title compound as a white solid, (1.35g), m.p. 87 - 89°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of compounds of formula (I), wherein R?1 and R2¿ each independently represent: hydrogen, C¿1-8?alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R?3R4NC¿2-6alkyl (where R?3 and R4¿ independently represent H or C¿1-4?alkyl) or NR?1R2¿ represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR5 (where R5 is H, C¿1-4?alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S, or C=O; n is 5 to 11; and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy, e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk?1)¿pA(Alk2)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent C¿1-4?alkyl which may be straight or branched and p and q are independently 0 or 1 provided that the length of -(Alk?1)¿pA(Alk2)q- does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group (a), in which Y?1 is Y2(CH¿2)r where r is 0 or 1 and Y2 is O, S or NR6 where R6 is hydrogen or C¿1-4?alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; with the provisos that (i) when X is O or S, and NR?1R2¿ represents a heterocyclic ring which does not contain an optional further heteroatom then Ar is phenyl substituted by a group Ph(Alk1)pC(O)(Alk2)q-; (ii) when n is 5 and one of R?1 and R2¿ is hydrogen, C¿1-4?alkyl or arylC1-4alkyl, then the other of R?1 and R2¿ is not R3R4NC2-6alkyl; and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for the treatment of a condition where a calcium antagonist is required. Certain novel compounds of formula (I) and processes for preparing them are also described.

Description

HETEROCYCLIC AMINES FOR TREATING ISCHAEMIC STROKES
The present invention relates to amine derivatives, more particularly aryloxy-, arylthio- or aroyl-alkylamino compounds, to processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the treatment of ischaemic stroke.
Stroke is reportedly the third most common cause of death in the developed world. Current therapies for ischaemic stroke are limited and have a number of disadvantages, such as the risk of exacerbating haemorrhage. There is therefore a need for new and improved treatments for ischaemic stroke.
EP- A- 103252 discloses a broad class of aryloxyalkylamino derivatives. These compounds are said to have utility as herbicides.
French Patent Application No. 1601591 describes a class of nitrogen-containing heterocyclic compounds derived from phenoxyalkyl alcohols, which are said to be cholesterol-lowering agents.
British Patent No. 924961 describes, as intermediates for the preparation of anti- nematodal agents, compounds of formula R.W.CH2.CH2.NXY, wherein R is phenyl optionally substituted by inter alia halogen, alkyl or alkoxy, X and Y are inter alia alkyl, or NXY represents a pyrrolidino, piperidino or morpholino group and W is a straight saturated chain containing up to 16 carbon atoms and 1 to 3 non-adjacent oxygen atoms.
We have now found that certain amine derivatives exhibit activity as calcium channel antagonists.
The present invention therefore provides, in a first aspect, the use of a compound of formula (I):
Figure imgf000003_0001
Formula (I) wherein
R.1 and R-2 each independently represent: hydrogen, Ci.galkyl, C3_gcycloalkyl, Cβ.gcycloalkylC^alkyl, arylCi-^alkyl, C2--6hydroxyalkyl or R3R4NC2-6--lky- (where R^ and R4 independently represent H or Cj^alkyl) or NR1R2 represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR-5, (where R5 is H, Cι_4alkyl or aϊylC^alkyl), which ring may optionally be substituted by one or two substituents selected from C 1 -ό^ yl and C .galkoxy ; X represents O, S, or C=O; n is 5 to 11 ; and
Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, Cj.galkyl, Ci.galkoxy, Cι_2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alkl)pA(Alk2)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent Cι_4alkyl which may be straight or branched and p and q are independently 0 or 1 , provided that the length of (Alk1)A(Alk2) does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group:
Figure imgf000004_0001
in which Y1 is Y2(CH2>r where r is 0 or 1 and Y2 is O, S or NR^ where R*-* is hydrogen or C^alkyl, Z is (CH2)S or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; with the provisos that (i) when X is O or S, and NR!R2 represents a heterocyclic ring which does not contain an optional further heteroatom then Ar is phenyl substituted by a group Ph(Alkl)pC(O)(Alk2)q-
(ii) when n is 5 and one of R* and R2 is hydrogen, C ι_4alkyl or arylC^alkyl, then the other of R1 and R2 is not R3R4NC2-6al yl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of conditions where a calcium antagonist is required.
Compounds of formula (I) and their pharmaceutically acceptable salts are preferably used in the manufacture of a medicament for the treatment of conditions related to the accumulation of calcium in the brain cells of mammals. In compounds of formula (I), n is preferably from 5 to 9, most preferably 7.
X preferably represents oxygen or C=O.
When Ar is substituted by a group Ph(Alk1)pA(Alk )q-, A is preferably oxygen, C=O or a bond. Alk1 and Alk2 preferably independently represent CH2 or when branched, C(H)(CH3) or C(CH3)2- When A is oxygen q is preferably zero and p is preferably zero or 1. When A is a bond the sum of p + q is preferably 1 or 2. When A represents CH=CH or C=O, p and q are preferably both zero.
Examples of tricyclic heteroaryl groups Ar include dibenzofuranyl, dibenzothienyl, carbazole, N-methylcarbazole, acridine and dibenzoxepine. The tricyclic moiety can be linked to the remainder of formula (I) via any suitable ring atom. Suitable substituents for Ph, and tricyclic heteroaryl groups include, for example, 1 to 3 substituents selected from halogen, trifluoro methyl, trifluoromethoxy, Cμ4alkyl and Cμ4alkoxy.
Preferably Ar is phenyl mono-substituted by a halogen atom or by a group selected from phenoxy, benzoyl, halobenzoyl or benzyl or benzyloxy in which the -CH2- moiety may optionally be substituted by one or two methyl groups; or Ar is phenyl disubstituted by a halogen atom; or Ar is 2-dibenzofuranyl. Most preferably Ar is phenyl substituted by benzyl, benzoyl, fluorobenzoyl, chlorobenzoyl or benzyloxy. The substituent is preferably at the 3- or 4- position of the phenyl ring. Alkyl groups present in the compounds of formula (I), alone or as part of another group, can be straight or branched. Thus, a C^galkyl group may be for example methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or any branched isomer thereof such as isopropyl, t-butyl, or sec-pentyl.
It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other non- pharmaceutically acceptable salts may be used for example in the isolation of a final product and are included within the scope of this invention.
It will be appreciated that the compounds of formula (I) may contain one or more asymmetric centres. Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. Certain compounds of formula (I) are believed to be novel. Thus, in a further aspect the invention provides novel compounds of formula (IA):
Figure imgf000005_0001
Formula (IA) wherein
R1, R2, n and Ar are as defined for formula (I); and salts thereof.
In a yet further aspect the invention also provides a compound of formula (IB) :
Figure imgf000006_0001
Formula (IB) and salts thereof, wherein R1, R2, and X are as defined for formula (I) and Ar1 represents phenyl optionally substituted by a group Ph(Alk1)pA(Alk2)q- or a tricyclic heteroaryl group as defined for formula (I), provided that when X is O or S, and NR-^R2 represents a heterocyclic ring which does not contain an optional further heteroatom then Ar1 is phenyl substituted by a group Ph(Alk1)pC(O)(Alk2)q-.
Particular compounds of the invention, which are believed to be novel compounds include: N-[7-(4-benzyloxyphenoxy)heptyl]-N-methylcyclohexylamine,
N-[7-(4-benzyloxyphenoxy)heptyl]methylamine,
N-[7-(4-benzyloxyphenoxy)heptyl]dimethylamine,
N-[7-(4-benzyloxyphenoxy)heptyl]--N-methyl-N,,N'-dimethylethylenediamine,
N-[7-(4-benzyloxyphenoxy)heptyl]-N-butylmethylamine, N-[7-(4-benzyloxyphenoxy)heptyl]morpholine,
N-[7-(4-benzyloxyphenoxy)heptyl]cyclohexylamine, l-[7-(4-benzyloxyphenoxy)heptyl]-4-methylpiperazine, l-[7-(4-benzoylphenoxy)heptyl]piperidine, l-[7-(3-benzoylphenoxy)heptyl]piperidine, 1 - { 7-[4-(4-fluorobenzoyl)phenoxy]heptyl } piperidine,
1 - { 7-[4-( 1 -Methyl- 1 -phenylethyl)phenoxy]heptyl } piperidine,
1 - { 7-[4-(4-chlorobenzoyl)phenoxy]heptyl } piperidine,
(+)- 1- { 7-[4-( 1 -phenylethyloxy]phenoxy]heptyl } piperidine,
6-[4-(4-fluorophenoxy)phenyl]-6-oxo-l-piperidinylhexane, 8-[4-(4-fluorophenoxy)phenyl]-8-oxo-l-piperidinyloctane,
6-(4-phenoxy)phenyl-6-oxo- 1 -piperidinylhexane, and salts thereof.
The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of a novel compound of formula (I) which comprises: (a) to prepare a compound wherein X represents O or S reaction of a compound of formula (II):
Figure imgf000006_0002
Formula (II) in which R1, R2, and n are as defined in formula (I), and L1 is a group displaceable with a nucleophile with a compound of formula (III) :
HXAr Formula (HI) in which Ar and X are as defined in formula (I);
(b) reaction of a compound of formula (IV) :
L (CH2)nXAr Formula (IV) in which Ar, X and n are as defined for formula (I),and L2 is a leaving group, with a compound of formula (V) :
Figure imgf000007_0001
Formula (V) in which R1 and R2 are as defined in formula (I); or (c) reduction of an amide of formula (VI) or (VII) :
O
R \
2 N(CH2)nXAr
R
Formula (VI)
Figure imgf000007_0002
Formula (VII) o
- . 7 ιι - wherein R1, R2, X, Ar and n are as defined above and R C is a group reducible to R1; d) Reductive amination of an aldehyde of formula (VIII) :
OHC-(CH2)n.iXAr
Formula (Vffl) wherein Ar, X, and n are as hereinbefore defined, in the presence of a compound of formula (V) as defined above. e) To prepare a compound wherein Ar represents phenyl substituted by
Ph(Alk1)pO-, alkylation of a compound of formula (IX) :
Figure imgf000008_0001
Formula (TX) wherein R1, R2, X, and n are as hereinbefore defined; with an alkylating agent of formula (X) : Ph(Alk1)pL1
Formula (X) wherein Ph, Alk1' p and L1 are as hereinbefore defined. 0 To prepare a compound where R*--R2N- represents an optionally substituted piperidine ring, reduction of a pyridine derivative of formula (XI) :
Figure imgf000008_0002
A— Formula (XI) wherein Ar, X, and n are as hereinbefore defined, R% represents hydrogen or an optional substituent as hereinbefore defined and A" is a counter anion; g) to prepare a compound where X represents O or S, reaction of a compound of formula (XII) :
R1 R2N(CH2)nXH
Formula (XII) wherein R , R2 and n are as hereinbefore defined and X is O or S, with a compound F-Ar; h) Interconversion of one compound of formula (I) to a different compound of formula (I) e.g.
(i) reduction of a compound wherein A represents CH=CH to a compound wherein A represents -CH2CH-2-;
(ii) reduction of a compound wherein A and/or X represent C=O to a compound wherein A and/or X represent -CH2-; followed if desired by salt formation. In process (a) the reaction between a compound of formula (II) and a compound of formula (IH) can be carried out under standard conditions. For example when L1 is hydroxy, the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine. Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1). This reaction may optionally be effected in the presence of a solvent such as tetrahydrofuran. Alternatively the leaving group L1 may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy. In this case the reaction may be effected in the absence or presence of solvent such as dimethylformamide or methylethylketone in the presence of a base such as sodium hydride or potassium carbonate and at a temperature in the range 0 to 200°C.
The reaction of a compound of formula (IV) with a compound of formula (V) according to process (b) may be effected in conventional manner, for example using excess amine as solvent or alternatively using an organic solvent, e.g. an alcohol such as methanol or ethanol; dimethylformamide, or chloroform. The leaving group L2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p- toluenesulphonyloxy. The reaction may be carried out in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide or an excess of the amine (V) may be employed. Reduction of an amide of formula (VI) or (VII) according to process (c) may be effected using a suitable reducing agent such as lithium aluminium hydride. It will be appreciated that in this case X or A should not represent C=O unless simultaneous reduction of X and/or A is desired.
In process (d) reductive amination of an aldehyde (Vlϋ) may be effected using a reducing agent such as sodium cyanoborohydride in the presence of a compound of formula (V), according to procedures well known in the art.
In process (e) the reaction of compounds (EX) and (X) may be effected in an analogous manner to process (a) described above.
Reduction of a pyridinium derivative (XI) according to process (f) may be effected for example by hydrogenation, using a noble metal catalyst such as palladium on charcoal, platinum or platinum oxide (Adam's catalyst), suitably in a solvent such as an alcohol e.g. ethanol.
In process (g) the reaction between a compound of formula (XII) and a compound F-Ar is preferably effected in the presence of a strong base such as sodium hydride, and in a polar organic solvent such as dimethylsulphoxide or dimethylformamide.
Interconversion reactions according to process (h) may be carried out using standard methods. Thus for example conversion of a compound (I) wherein A represents -CH=CH- into a compound (I) wherein A represents -CH2CH2- may be effected by catalytic hydrogenation and reduction of a compound where X and/or A represents C=O may be effected using a suitable reducing agent such as lithium aluminium hydride.
A compound of formula (II) can be prepared under standard alkylation conditions by reacting a compound of formula (XIII) :
Figure imgf000010_0001
Formula (Xm) in which I- L2 and n are as hereinbefore defined, with a compound of formula (V) as hereinbefore defined. The reaction is suitably carried out under analogous conditions to those described above for process (b).
It will be appreciated that in compounds of formula (XDI) the leaving groups L1 and L2 are preferably selected so that the compound of formula (V) reacts selectively with L2. For example, in a compound of formula (XIII) L1 is suitably hydroxy and L2 is suitably halo.
Compounds of formula (III) are commercially available or may be prepared using standard procedures well known in the art.
Compounds of formula (IV) can be prepared by reacting a compound of formula (HI) as hereinbefore defined with a compound of formula (XIII) as hereinbefore defined. In this reaction both L and L2 can be identical, for example halo. The reaction is suitably carried out in the presence of a weak base such as potassium carbonate. Alternatively the reaction may be carried out under phase transfer conditions using a strong base such as potassium hydroxide. Alternatively where X represents C=O a compound of formula (TV) may be prepared by Friedel-Craft acylation of a compound HAr with an acylating agent of the formula L2(CH2)nC(O)Hal, where Hal represents a halogen atom such as bromo or chloro. The carbonyl group in the resulting compound of formula (IV) may if desired subsequently be reduced.
Compounds of formula (V) and (XIII) are commercially available or may be prepared by standard methods. Compounds of formula (VI) may be prepared according to general processes (a) and (b) described herein employing an appropriate amide corresponding to formula (II) or (V).
Compounds of formula (VII) may be prepared by acylation of a compound of formula (V) for example with an appropriate acid chloride or ester, which may itself be prepared from a compound of formula (IE) by reaction with an appropriate, commercially available bromoalkyl ester or acid, followed if necessary or desired by conversion to an acid chloride. Alternatively a compound (VII) may be prepared by a method analogous to process (a). An aldehyde of formula (VI-O) may be prepared for example by reduction of the corresponding nitrile using a reducing agent such as diisobutyl aluminium hydride, in the presence of an inert solvent such as toluene. Conveniently reductive animation of the aldehyde is carried out in situ, i.e. the compound of formula (I) is obtained from the nitrile in a one-pot reaction without isolation of the intermediate aldehyde. The nitrile may itself be prepared by reacting a compound of formula (IV) wherein L2 is halo with potassium cyanide. Compounds (VTfl) may also be prepared by other standard procedures such as reduction of an ester or oxidation of an alcohol.
Compounds of formula (IX) may be prepared by methods analogous to any of processes (a) - (d) described herein. Alternatively a compound (IX) may be obtained by catalytic hydrogenation of a corresponding compound of formula (I) wherein Ar represents a benzyloxyphenyl group. This therefore provides a further method of converting a compound of formula (I) to a different compound of formula (I).
Compounds of formula (X) are commercially available or are known in the literature.
Compounds of formula (XI) may be prepared in a similar manner to process (b) described above, employing a substituted pyridine as the amine.
Compounds of formula (XII) may be prepared as described for compounds of formula (II). It will be appreciated that during certain of the above processes (a) to (h) as well as during the preparation of intermediates it may be necessary to protect any unsubstituted nitrogen atoms present in the molecule, with for example an N-protecting group, which may subsequently removed by methods well known in the art. Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, t- butoxycarbonyl or benzyloxycarbonyl. An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis.
When a compound of formula (I) is obtained as a mixture of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
The invention also encompasses any novel intermediates described herein, in particular those of formulae (II), (IV), (VI), (VII), (IX) and (XI).
Compounds of the invention have been found to exhibit high calcium influx blocking activity, for example in neurons. As such the compounds are expected to be of use in therapy in treating conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal. The invention also provides a method of treatment of conditions or diseases related to (e.g. caused or exacerbated by) the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof.
Thus for example, the present invention provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, visceral pain, epilepsy, traumatic head or spinal injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, mood disorders and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. For use in medicine, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a novel compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient The compounds of the invention may be administered by any convenient method for example by oral, parenteral, buccal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. Parenteral administration is generally preferred.
The compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid caπier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be. prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Both liquid and solid compositions may contain other excipients known in the pharmaceutical art, such as cyclodextrins.
Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Alternatively the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 400 mg per day. Thus the total daily dosage by oral administration could be in the range 1 to 2000 mg and the total daily dosage by parenteral administration could be in the range 0.1 to 400 mg. The compounds may be administered for a period of continuous therapy, for example for a week or more.
If desired a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination or concurrently with one or more other therapeutic agents, for example a thrombolytic agent such as anistreplase, streptokinase or a tissue plasminogen activator; an excitatory amino acid antagonist such as an NMDA antagonists; a free radical inhibitor; or a calpain inhibitor. BIOLOGICAL DATA
In Vitro
Ca2+ Current Measurement
Cell preparations Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Forda et al, Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto glass coverslips and used within 3 days to permit effective voltage clamp of Ca + currents. Superior cervical ganglion neurons were isolated and cultured following a method modified from Marrion et al, Neurosci. Lett., 77, 55-60 (1987). Cells were plated onto laminin coated plastic tissue culture dishes and incubated at 37°C until just prior to recording. Electrophysiological recordings were performed from 2 to 9 days after dissociation.
Solutions The pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl2, 4; ATP, 2; buffered to pH 7.2 with CsOH. Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca2+ currents. The external solution for recording Ca + channel currents contained in mM: BaCl2, 10; TEA-C1, 130; glucose, 10; HEPES, 10; MgCl2, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided. Compounds were dissolved in DMSO to make a 20 mM stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca + currents. All experiments were performed at 21 to 24°C. Whole cell currents were recorded using List EPC-7 amplifiers and stored, digitised for later analysis using PC based software similar to that described previously (Benham & Tsien, Journal of Physiology (1988), 404, 767-784).
Ca-2+ currents Peak voltage gated Ca + channel cunrents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba2+ as charge carrier. Currents were evoked from a holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow rundown of current as is commonly seen when recording Ca + currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a rundown corrected control value. Dorsal Root Ganglion Cells
Block by 20 μM drug was assessed 3 minutes after drug application. In this test compounds of Examples 1 to 10 gave percentage inhibition of plateau Ca2+ current in the range 62-99%.
Superior Cervical Ganglion Cells
Once a constant calcium current had been recorded for 4 successive pulses (1 minute) 10 μM Nimodipine, a dihydropyridine, was applied to the cell to block L type calcium current. After three minutes 5μM drug was coapplied with lOμM Nimodipine for three minutes. Such drug application tested the block of the remaining, predominantly N type, calcium current.
In this test compounds of Examples 9 to 15 gave percentage inhibition of plateau Ca + current in the range 70 to 96%.
Pharmaceutical Formulations
The following represent typical pharmaceutical formulations according to the present invention, which may be prepared using standard methods.
IV Infusion
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Solvent/complexing to 100 ml
Bolus Injection
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Co-Solvent to 5 ml
Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
Solvent : Typically water but may also include cyclodextrins (1-100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol.
Tablet
Compound 1 - 40 mg
Diluent/Filler * 50 - 250 mg Binder 5 - 25 mg
Disentegrant * 5 - 50 mg
Lubricant 1 - 5 mg
Cyclodextrin 1 - 100 mg
* may also include cyclodextrins
Diluent : e.g. Microcrystalline cellulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
Disintegrant : e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
Compound 1 - 40 mg
Suspending Agent 0.1 - 10 mg
Diluent 20 - 60 mg Preservative 0.01 - 1.0 mg
Buffer to pH ca 5 - 8
Co-solvent 0 - 40 mg
Flavour 0.01 - 1.0 mg
Colourant 0.001 - 0.1 mg
Suspending agent :e.g. Xanthan gum, microcrystalline cellulose
Diluent : e.g. sorbitol solution, typically water
Preservative : e.g. sodium benzoate
Buffer : e.g. citrate Co-solvent : e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
The invention is further illustrated by the following non-limiting examples:
Intermediate 1
7-(4-Benzyloxyphenoxy)-l-bromoheptane
1,7-Dibromoheptane (12.9g) was added dropwise to a stirred solution of 4- benzyloxyphenol (lOg), sodium hydroxide (2.5g), benzyltriethylammonium chloride (0.4g) and water (30ml). The mixture was stirred at 50°C for 18 hours, water (50ml) added and the solution extracted with dichloromethane (2 x 100ml). The combined dichloromethane extracts were dried over magnesium sulphate, solvent was removed and the residue was chromatographed on silica gel eluted with hexane/dichloromethane to give the title compound (4.25g) as a solid, m.p. 56 - 59°C.
Intermediate 2
7-PiperidinoheptanoI
7-Bromoheptanol (5.0g) was added over 30 minutes to piperidine (20ml) stirred at room temperature. The resulting mixture was left to stand for 60 hours and then dissolved in chloroform. This solution was washed with dilute sodium hydroxide solution, brine containing a few drops of dilute sodium hydroxide solution and dried over magnesium sulphate. The solvent was removed and the residue was Kugelrohr distilled to give the title compound as a solid (4.53g) m.p. 37-39°C.
Intermediate 3 l-Bromo-6-[4-(4-fluorophenoxy)phenyl]-6-oxyhexane
A mixture of aluminium chloride (4.0g) in dry dichloromethane under an atmosphere of argon was treated with 6-bromohexanoyl chloride (6.4ml). The resulting solution was stirred for 20 minutes then added to a solution of 4-fluorodiphenylether (5g) in dichloromethane (100ml). The addition took 20 minutes and the mixture was stirred for a further 18 hours. The mixture was treated with water and the organic phase was separated, washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent removed. Recrystallisation from ethyl acetate-hexane gave the title compound as a white solid, (6.04g), m.p. 85 - 87°C.
Found: C, 59.02; H, 5.03% (Ci H!gBrFO2) requires: C, 59.19; H, 4.97% Intermediate 4 l-Bromo-8-[4-(4-fluorophenoxy)phenyl]-8-oxyoctane
Using similar conditions to the preparation of Intermediate 3 starting from 8-bromooctanyl chloride (7.24g) and using corresponding molar amounts of the other reagents gave the title compound as an oil (11.06g) which was used without further purification.
Intermediate 5 l-Bromo-6-(4-phenoxy)phenyl-6-oxyhexane
Using the conditions used to prepare Intermediate 3 starting from 6-bromooctanoyl chloride (20g) and using corresponding molar amounts of the other reagents gave the title compound as an oil which was used without further purification.
Example 1 N-[7-(4-Benzyloxyphenoxy)heptyl]-N-methylcyclohexylamine hydrochloride A mixture of 7-(4-benzyloxyphenoxy)-l-bromoheptane (1.88g), 80% sodium hydride (0.17g) and dimethylformamide (10ml) was stirred under nitrogen for 5 minutes. N- methylcyclohexylamine (0.65ml) was added by syringe and the mixture was stirred at 60°C for 4 hours. The solvent was removed and the residue treated with water and extracted with ether. The ether layer was separated, treated with dilute hydrochloric acid and the resulting solid was collected, chromatographed on silica gel eluted with dichloromethane-methanol and recrystallised from ethyl acetate to give the title compound, (0.674g) m.p. 107 - 108°C. Found: C, 72.37; H, 8.86; N, 3.40 ; Cl, 7.78% (C27H39NO2.HCI) requires: C, 72.70; H, 9.04; N, 3.14; Cl, 7.95%
Example 2
N-[7-(4-Benzyloxyphenoxy)heptyl]methylamine hydrochloride
A solution of 7-(4-benzyloxyphenoxy)-l-bromoheptane (1.25g) in chloroform (20ml) methanol (10ml) and ethanol (10ml) was treated with 8M methylamine in ethanol (20ml). The solution was allowed to stand at room temperature for 60 hours, the solvent was removed and the residue dissolved in chloroform. This solution was washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent was removed. The residue was dissolved in ethyl acetate, treated with ethereal hydrogen chloride and the resulting solid was recrystallised from ethanol to give the title compound as white needles, (0.626g), m.p. 175 -176°C. Found: C, 69.42; H, 8.11; N, 4.01; Cl', 9.68% (C21H29NO2.HCI) requires: C, 69.31; H, 8.31; N, 3.85; Cl", 9.74%
Example 3
N-[7-(4-Benzyloxyphenoxy)heptyl]dimethylamine hydrochloride The title compound was prepared in a similar manner to Example 2 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.25g), 33% dimethylamine in ethanol (10ml) and chloroform (50ml). Treatment with ethereal hydrogen chloride and recrystallisation from acetonitrile gave the title compound as a white solid, (0.638g), m.p. 152 - 153°C. Found: C, 68.23; H, 8.37; N, 3.71; Cl, 9.24% (C22H31NO2.HCI.O.5H2O) requires: C, 68.28; H, 8.59; N, 3.62; Cl, 9.16%
Example 4
N-[7-(4-Benzyloxyphenoxy)heptyl]-N-methyI-N',N'-dimethylethylenediamine dihydrochloride The title compound was prepared in a similar manner to Example 2 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.25g), N,N,N'-trimethylethylenediamine (0.37g) and chloroform (100ml). Treatment with ethereal hydrogen chloride and recrystallisation from ethyl acetate gave the title compound as a white solid, (0.55g), m.p. 242 - 244°C. Found: C, 61.78; H, 7.99; N, 5.75% (C25H3gN2O2.2HC1.0.8H2O) requires: C, 61.71; H, 8.40; N, 5.75%
Example 5
N-[7-(4-Benzyloxyphenoxy)heptyl]-N-butylmethylamine oxalate
A mixture of 7-(4-benzyloxyphenoxy)-l-bromoheptane (l.Og), N-butylmethylamine (0.25g), potassium carbonate (2g) and ethanol (25ml) was stirred at reflux for 18 hours. The mixture was filtered and the residue was washed with ethanol. The filtrates were combined, the solvent removed and the residue partitioned between ether and dilute sodium hydroxide solution. The ether layer was separated, dried over magnesium sulphate and the solvent removed. Chromatography on silica gel eluted with methanol/dichloromethane and treatment with oxalic acid gave a white solid which was recrystallised from ethyl acetate to give the title compound,. (0.25g), m.p. 141 - 143°C. Found: C, 67.79; H, 8.07; N, 3.08% (C25H37NO2.C2H2O4.O.25H2O) requires: C, 67.76; H, 8.15; N, 2.92% Example 6
N-[7-(4-Benzyloxyphenoxy)heptyl]morpholine hydrochloride
The title compound was prepared in a similar manner to Example 5 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.5g), morpholine (3.0g), potassium carbonate (3g) and ethanol (50ml). Chromatography on silica gel eluted with methanol/dichloromethane and treatment with ethereal hydrogen chloride gave a white solid which was recrystallised from ethyl acetate to provide the title compound. (0.85g), m.p. 174 - 176°C. Found: C, 68.38; H, 7.95; N, 3.40; Cl, 8.45% (C24H33NO3.HCI) requires: C, 68.64; H, 8.16; N, 3.33; Cl, 8.44%
Example 7
N-[7-(4-Benzyloxyphenoxy)heptyl]cyclohexylamine hydrochloride
The title compound was prepared in a similar manner to Example 1 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.88g), 80% sodium hydride (0.17g), cyclohexylamine (0.572ml) and dimethylformamide (10ml). Treatment with ethereal hydrogen chloride and recrystallisation from n-propanol followed by further recrystallisation from ethanol gave the title compound as a white solid, (0.505g), m.p. 155 - 156°C. Found: C, 72.14; H, 8.65; N, 3.45 ; Cl, 8.41% (C26H37NO2.HCI) requires: C, 72.28; H, 8.87; N, 3.24; Cl, 8.21%
Example 8 l-[7-(4-Benzyloxyphenoxy)heptyI]-4-methyIpiperazine dihydrochloride
The title compound was prepared in a similar manner to Example 1 starting from 7-(4- benzyloxyphenoxyH-bromoheptane (1.88g), 80% sodium hydride (0.17g), N- methylpiperazine (0.55ml) and dimethylformamide (10ml). Treatment with ethereal hydrogen chloride and recrystallisation from ethanol gave the title compound as a white solid, (0.93g), m.p. 238 - 241 °C.
Found: C, 62.83; H, 7.81; N, 5.98; Cl, 14.80% (C25H36N2O2.2HCI.O.5H2O) requires: C, 62.75; H, 8.21; N, 5.85; Cl, 14.82%
Example 9 l-[7-(4-Benzoylphenoxy)heptyI]piperidine hydrochloride
A solution of 7-piperidinoheptanol (2.0g), 4-hydroxybenzophenone (1.98g), triphenylphosphine (2.62g) in tetrahydrofuran (100ml) was treated with diethyl azodicarboxylate (1.74g). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised from acetonitrile to give the title compound (2.5 lg) as white needles, m.p. 178 -180°C.
Found: C, 72.36; H, 7.96; N, 3.59; Cl, 8.51%. (C25H33NO2.HCI) requires: C, 72.18; H, 8.23; N, 3.37; Cl, 8.52%
Example 10 l-[7-(3-Benzoylphenoxy)heptyI]piperidine hydrochloride
A solution of 7-piperidinoheptanol (2.0g), 3-hydroxybenzophenone (1.98g), triphenylphosphine (2.62g) in tetrahydrofuran (100ml) was treated with diethyl azodicarboxylate (1.74g). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised from acetonitrile to give the title compound (1.99g) as white needles, m.p. 88 - 90°C. Found: C, 72.05; H, 7.89; N, 3.45; Cl, 8.54%. (C25H33NO2.HCI) requires: C, 72.18; H, 8.23; N, 3.37; Cl, 8.52%
Example 11 l-{7-[4-(4-Fluorobenzoyl)phenoxy]heptyI}piperidine hydrochloride
A mixture of 7-piperidinoheptanol (l.Og), 80% sodium hydride in oil (0.15g) and dimethylsulphoxide (25ml) was stirred at 40°C under an atmosphere of argon for 2 hours. The mixture was allowed to cool to room temperature, treated with 4,4'- difluorobenzophenone (2.18g) and stirred for 18 hours. The solvent was removed and the residue treated with water and extracted with ether. The ether layer was washed with water and brine, dried over sodium sulphate and the solvent was removed. Chromatography on silica gel eluted with 10% methanol in chloroform followed by treatment with ethereal hydrogen chloride and recrystallisation from acetonitrile gave the title compound as cream coloured needles, (0.946g), m.p. 166 - 167°C. Found: C, 68.87; H, 7.41; N, 3.46 ; Cl, 8.05% (C25H32FNO2.HCI) requires: C, 69.18; H, 7.66; N, 3.22; Cl, 8.17% Example 12 l-{7-[4-(l-Methyl-l-phenylethyl)phenoxy]heptyl}piperidine hydrochloride
A solution of 7-piperidinoheptanol (l.Og), 4-cumylphenol (1.07g), triphenylphosphine
(1.31g) in tetrahydrofuran (20ml) was treated with diethyl azodicarboxylate (0.87g). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with 10% methanol in chloroform. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride.
The precipitate was collected by filtration and recrystallised from ethyl acetate to give the title compound (l.llg) as a white solid, m.p. 122 -124°C. Found: C, 75.03; H, 9.16; N, 3.47; Cl, 8.21%.
(C27H39NO.HCI) requires: C, 75.41; H, 9.37; N, 3.26; Cl, 8.24%
Example 13 l-{7-[4-(4-Chlorobenzoyl)phenoxy]heptyl}piperidine hydrochloride A solution of 7-piperidinoheptanol (l.Og), 4-chloro-4'-hydroxybenzophenone (1.16g), triphenylphosphine (1.31g) in tetrahydrofuran (20ml) was treated with diethyl azodicarboxylate (0.87g). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with 10% methanol in chloroform. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised from acetonitrile to give the title compound (1.13g) as white needles, m.p. 194 -195°C. Found: C, 66.20; H, 7.09; N, 3.44; Cl", 7.82%. (C25H32CINO2.HCI) requires: C, 66.66; H, 7.38; N, 3.11; Cl", 7.82%
Example 14
(+)-l-{7-[4-(l-Phenylethyloxy]phenoxy]heptyl}piperidine hydrochloride A solution of 7-(4-hydroxyphenoxy)-l-piperidinoheptane (WO93/22302; 0.75g), (±)-l- phenylethanol (0.3 lg), triphenylphosphine (0.61g) in tetrahydrofuran (20ml) was treated with diethyl azodicarboxylate (0.44g). The resulting solution was stiιτed at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with 10% methanol in chloroform. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised from isopropyl acetate to give the title compound (0.303g) as a white solid, m.p. 101 - 103°C. Found: C, 72.14; H, 8.67; N, 3.42; Cl, 8.21%.
(C26H37NO2.HCI) requires: C, 72.28; H, 8.87; N, 3.24; Cl, 8.20% Example 15
6-[4-(4-Fluorophenoxy)phenyl]-6-oxo-l-piperidinylhexane hydrochloride
A solution of l-bromo-6-[4-(4-fluorophenoxy)phenyl]-6-oxyhexane (2.0g) in dichloromethane (100ml) was treated with piperidine (3.0ml). The solution was allowed to stand at room temperature for 18 hours, washed with dilute sodium hydroxide solution and brine, dried over sodium sulphate and the solvent was removed. The resulting oil was dissolved in ethyl acetate and treated with ethereal hydrogen chloride and the solvent was removed. The residue was chromatographed on silica gel eluted with 10% methanol in dichloromethane and crystallised by trituration with ether to give the title compound as an off-white solid, (1.378g), m.p. 151 - 152°C. Found: C, 67.44; H, 7.01; N, 3.61% (C23H2gFNO2.HC1.0.25H2O) requires: C, 67.30; H, 7.24; N, 3.41%
Example 16
8-[4-(4-Fluorophenoxy)phenyl]-8-oxo-l-piperidinyloctane hydrochloride
The title compound was prepared in a similar manner to Example 15 starting from 1- bromo-8-[4-(4-fluorophenoxy)phenyl]-8-oxyoctane (2.0g) and using corresponding molar amounts of the other reagents. Treatment with ethereal hydrogen chloride and crystallisation under ether gave the tide compound as a white solid, (1.53g), m.p. 111 - 112°C.
Found: C, 67.95; H, 7.43; N, 3.52% (C25H32FNO2.Ha-O.3H2O) requires: C, 68.24; H, 7.69; N, 3.18%
Example 17
6-(4-Phenoxy)phenyl-6-oxo-l-piperidinylhexane hydrochloride
The title compound was prepared in a similar manner to Example 15 starting from 1- bromo-6-(4-phenoxy)phenyl-6-oxyhexane (1.5g) and using corresponding molar amounts of the other reagents. Treatment with ethereal hydrogen chloride and crystallisation under ether gave the title compound as a white solid, (1.35g), m.p. 87 - 89°C.

Claims

Claims
1. The use of a compound of formula (I):
Figure imgf000025_0001
Formula (I) wherein
R1 and R2 each independently represent: hydrogen, Ci.galkyl, C3.gcycl0a.kyl, C3_gcycloalkylCι_4alkyl, arylCμ4alkyl, C2-6hydroxyalkyl or R3R4NC2-6alkyl (where R3 and R4 independently represent H or C i^alkyl) or NR-ΪR2 represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR-5, (where R5 is H, Chalky! or arylCi^alkyl), which ring may optionally be substituted by one or two substituents selected from Ci.galkyl and C^galkoxy; X represents O, S, or C=O; n is 5 to 11 ; and
Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, Ci.galkyl, C .galkoxy, Cι_2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk1)pA(Alk )q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk1 and Alk2 independently represent Cι_4alkyl which may be straight or branched and p and q are independently 0 or 1 provided that the length of -(Alk )pA(Alk )q. does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group:
Figure imgf000025_0002
in which Y1 is Y (CH2)r where r is 0 or 1 and Y2 is O, S or NR6 ere R^ is hydrogen or Cι_4alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; with the provisos that
(i) when X is O or S, and NR-^R2 represents a heterocyclic ring which does not contain an optional further heteroatom then Ar is phenyl substituted by a group Ph(Alk1)pC(O)(Alk2)q-
(ii) when n is 5 and one of R1 and R2 is hydrogen, Cι_4alkyl or arylC1.4a.lkyl, then the other of R1 and R2 is not R3R4NC2-6 lkyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of a condition where a calcium antagonist is required.
2. Use according to claim 1 wherein the condition is related to the accumulation of calcium in the brain cells of a mammal.
3. Use of a compound according to claim 1 or claim 2 wherein n is from 5 to 9.
4. Use of a compound according to any of claims 1 to 3 wherein X represents oxygen or C=O.
5. Use of a compound according to any of claims 1 to 4 wherein Ar represents phenyl substituted by a group Ph(Alk1)pA(Alk )q-.
A compound of formula (IA):
Figure imgf000026_0001
Formula (IA) wherein R1, R2, n and Ar are as defined for formula (I); or a salt thereof.
7. A compound of formula (IB) :
Figure imgf000026_0002
Formula (IB) wherein R1, R2, and X are as defined for formula (I) and Ar1 represents phenyl optionally substituted by a group Ph(Alk1)pA(Alk2)q- or a tricyclic heteroaryl group as defined for formula (I), provided that when X is O or S, and NR-^R2 represents a heterocyclic ring which does not contain an optional further heteroatom then Ar1 is phenyl substituted by a group Ph(Alk1)pC(O)(Alk )q-, or a salt thereof.
8. A compound of formula (I) selected from : N-[7-(4-benzyloxyphenoxy)heptyl]-N-methylcyclohexylamine, N-[7-(4-benzyloxyphenoxy)heptyl]methylamine,
N-[7-(4-benzyloxyphenoxy)heptyl]dimethylamine,
N-[7-(4-benzyloxyphenoxy)heptyl]-N-methyl-N',N'-dimethylethylenediamine,
N-[7-(4-benzyloxyphenoxy)heptyl]-N-butylmethylamine, N-[7-(4-benzyloxyphenoxy)heptyl]morpholine,
N-[7-(4-benzyloxyphenoxy)heptyl]cyclohexylamine, l-[7-(4-benzyloxyphenoxy)heptyl]-4-methylpiperazine, l-[7-(4-benzoylphenoxy)heptyl]piperidine, l-[7-(3-benzoylphenoxy)heptyl]piperidine, 1- { 7-[4-(4-fluorobenzoyl)phenoxy]heptyl } piperidine,
N- { 7-[4-(4-fluorobenzyl)-phenoxy]heptyl } piperidine,
1 - { 7-[4-( 1 -methyl- 1 -phenylethyl)phenoxy]heptyl } piperidine,
1 - { 7-[4-(4-chlorobenzoyl)phenoxy]heptyl } piperidine
(±)- 1 - { 7-[4-( 1 -phenylethyloxy] phenoxyjheptyl } piperidine, 6-[4-(4-fluorophenoxy)phenyl]-6-oxo- 1-piperidinylhexane,
8-[4-(4-fluorophenoxy)phenyl]-8-oxo-l-piperidinyloctane,
6-(4-phenoxy)phenyl-6-oxo- 1 -piperidinylhexane or a salt thereof.
9. A process for the preparation of a novel compound of formula (I) which comprises:
(a) to prepare a compound wherein X represents O or S reaction of a compound of formula (II):
Figure imgf000027_0001
Formula (II) in which R1, R2, and n are as defined in formula (I), and L1 is a group displaceable with a nucleophile with a compound of formula (lTf) :
HXAr Formula (HI) in which Ar and X are as defined in formula (I);
(b) reaction of a compound of formula (TV) :
UCH2)πXAr Formula (IV) in which Ar, X and n are as defined for formula (I),and L2 is a leaving group, with a compound of formula (V) :
Formula (V) in which R1 and R2 are as defined in formula (I); or
(c) reduction of an amide of formula (VI) or (VII) :
Figure imgf000028_0001
Formula (VI)
Figure imgf000028_0002
Formula (VII)
O wherein R1, R2, X, Ar and n are as defined above and R C is a group reducible to R1; d) Reductive amination of an aldehyde of formula (VIII) :
OHC-(CH2)n-iXAr
Formula (Vπi)
wherein Ar, X, and n are as hereinbefore defined, in the presence of a compound of formula (V) as defined above. e) To prepare a compound wherein Ar represents phenyl substituted by Ph(Alk1)pO-, alkylation of a compound of formula (DC) :
Figure imgf000028_0003
Formula (IX) wherein R1, R2, X, and n are as hereinbefore defined; with an alkylating agent of formula (X) :
Ph(Alk1)pL1 Formula (X) wherein Ph, Alk1, p and L1 are as hereinbefore defined. f) To prepare a compound where R-^N- represents an optionally substituted piperidine ring, reduction of a pyridine derivative of formula (XI) :
Figure imgf000029_0001
A-
Formula (XI) wherein Ar, X, and n are as hereinbefore defined, R-- represents hydrogen or an optional substituent as hereinbefore defined and A" is a counter anion; g) to prepare a compound where X represents O or S, reaction of a compound of formula (XII) :
R1 R2N(CH2)nXH
Formula (XII) wherein R , R2 and n are as hereinbefore defined and X is O or S, with a compound F-Ar; h) Interconversion of one compound of formula (I) to a different compound of formula (I) e.g.
(i) reduction of a compound wherein A represents CH=CH to a compound wherein A represents -CH2CH2
(ii) reduction of a compound wherein A and or X represent C=O to a compound wherein A and/or X represent -CH2-; followed if desired by salt formation.
10. A pharmaceutical composition comprising a novel compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
11. A method of treatment of a condition or disease related to the accumulation of calcium in the brain cells of a mammal which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as defined in any of claims 1 or 3 to 8 or a pharmaceutically acceptable salt thereof.
PCT/EP1994/003425 1993-10-22 1994-10-18 Heterocyclic amines for treating ischaemic strokes WO1995011238A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94929558A EP0724577A1 (en) 1993-10-22 1994-10-18 Heterocyclic amines for treating ischaemic strokes
JP7511321A JPH09504016A (en) 1993-10-22 1994-10-18 Heterocyclic amines for ischemic stroke treatment
AU78566/94A AU7856694A (en) 1993-10-22 1994-10-18 Heterocyclic amines for treating ischaemic strokes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321811A GB9321811D0 (en) 1993-10-22 1993-10-22 Pharmaceuticals
GB9321811.3 1993-10-22

Publications (1)

Publication Number Publication Date
WO1995011238A1 true WO1995011238A1 (en) 1995-04-27

Family

ID=10743963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/003425 WO1995011238A1 (en) 1993-10-22 1994-10-18 Heterocyclic amines for treating ischaemic strokes

Country Status (6)

Country Link
EP (1) EP0724577A1 (en)
JP (1) JPH09504016A (en)
AU (1) AU7856694A (en)
GB (1) GB9321811D0 (en)
WO (1) WO1995011238A1 (en)
ZA (1) ZA948233B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755923A1 (en) * 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO1997027179A2 (en) * 1996-01-26 1997-07-31 Novartis Ag Antiretroviral bases
WO2000063157A1 (en) * 1999-04-16 2000-10-26 Shiseido Company, Ltd. Disubstituted benzene derivatives
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
WO2003018538A1 (en) * 2001-08-31 2003-03-06 Ajinomoto Co., Inc. Novel diarylalkene derivatives and novel diarylalkane derivatives
WO2011054804A2 (en) 2009-11-09 2011-05-12 Unilever Plc Skin care compositions comprising phenoxyalkyl amines
WO2011054805A1 (en) 2009-11-09 2011-05-12 Unilever Plc Substituted 3-(phenoxymethyl) benzyl amines and personal care compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB924961A (en) * 1959-03-13 1963-05-01 Wellcome Found Quaternary ammonium compounds, the preparation thereof and pharmaceutical compositions thereof
FR1601591A (en) * 1968-12-24 1970-08-31 Hypocholesterolaemic phenoxyalkylamines
GB2113680A (en) * 1981-12-24 1983-08-10 Delalande Sa New aromatic derivatives comprising an aminoalkoxy chain having an activity antagomistic to calcium
EP0103252A2 (en) * 1982-09-11 1984-03-21 BASF Aktiengesellschaft Aryloxyalkyl amines, process for their preparation and their use in combating unwanted plant growth
EP0302792A2 (en) * 1987-08-07 1989-02-08 Sanofi Alkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same
EP0382629A1 (en) * 1989-02-07 1990-08-16 Elf Sanofi Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them
WO1993022302A1 (en) * 1992-04-24 1993-11-11 Smithkline Beecham Plc N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB924961A (en) * 1959-03-13 1963-05-01 Wellcome Found Quaternary ammonium compounds, the preparation thereof and pharmaceutical compositions thereof
FR1601591A (en) * 1968-12-24 1970-08-31 Hypocholesterolaemic phenoxyalkylamines
GB2113680A (en) * 1981-12-24 1983-08-10 Delalande Sa New aromatic derivatives comprising an aminoalkoxy chain having an activity antagomistic to calcium
EP0103252A2 (en) * 1982-09-11 1984-03-21 BASF Aktiengesellschaft Aryloxyalkyl amines, process for their preparation and their use in combating unwanted plant growth
EP0302792A2 (en) * 1987-08-07 1989-02-08 Sanofi Alkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same
EP0382629A1 (en) * 1989-02-07 1990-08-16 Elf Sanofi Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them
WO1993022302A1 (en) * 1992-04-24 1993-11-11 Smithkline Beecham Plc N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755923A4 (en) * 1995-01-23 1997-04-09 Suntory Ltd Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
US6048876A (en) * 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
US6469010B1 (en) 1995-01-23 2002-10-22 Suntory Limited Medicament for the alleviation or treatment of symptom derived from the ischemic disease and compound useful thereof
EP0755923A1 (en) * 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO1997027179A2 (en) * 1996-01-26 1997-07-31 Novartis Ag Antiretroviral bases
WO1997027179A3 (en) * 1996-01-26 1997-12-31 Ciba Geigy Ag Antiretroviral bases
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6469038B1 (en) 1998-03-11 2002-10-22 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6989448B2 (en) 1998-03-11 2006-01-24 Lain-Yen Hu Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
WO2000063157A1 (en) * 1999-04-16 2000-10-26 Shiseido Company, Ltd. Disubstituted benzene derivatives
WO2003018538A1 (en) * 2001-08-31 2003-03-06 Ajinomoto Co., Inc. Novel diarylalkene derivatives and novel diarylalkane derivatives
US7462630B2 (en) 2001-08-31 2008-12-09 Ajinomoto Co., Inc. Diarylalkene derivatives and novel diarylalkane derivatives
US8278329B2 (en) 2001-08-31 2012-10-02 Ajinomoto Co., Inc. Diarylalkene derivatives and novel diarylalkane derivatives
WO2011054804A2 (en) 2009-11-09 2011-05-12 Unilever Plc Skin care compositions comprising phenoxyalkyl amines
WO2011054805A1 (en) 2009-11-09 2011-05-12 Unilever Plc Substituted 3-(phenoxymethyl) benzyl amines and personal care compositions
US8309064B2 (en) 2009-11-09 2012-11-13 Conopco, Inc. Skin care compositions comprising phenoxyalkyl amines
US8425885B2 (en) 2009-11-09 2013-04-23 Conopco, Inc. Substituted 3-(phenoxymethyl) benzyl amines and personal care compositions

Also Published As

Publication number Publication date
GB9321811D0 (en) 1993-12-15
AU7856694A (en) 1995-05-08
ZA948233B (en) 1995-07-25
JPH09504016A (en) 1997-04-22
EP0724577A1 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
AP279A (en) 4 substituted piperidine derivatives, processes for their preparation pharmaceutical compositions containing them and their use in therapy.
US4308387A (en) Diphenylbutyl-piperzinecarboxamides
US6469010B1 (en) Medicament for the alleviation or treatment of symptom derived from the ischemic disease and compound useful thereof
NL8000754A (en) NEW SUBSTITUTED PIPERIDINE DERIVATIVES WITH THERAPEUTIC EFFECT, PREPARATIONS CONTAINING THESE NEW SUBSTANCES, AND METHOD FOR THE PREPARATION AND USE THEREOF.
AU649468B2 (en) 3-substituted piperidine derivatives
US4879300A (en) Novel piperidine derivatives
EP0629190A1 (en) Compounds as calcium channel antagonists
EP0399414B1 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
US5773463A (en) Indane and tetrahydronaphthalene derivatives as calcium channel antagonists
AU5833494A (en) Piperidine derivatives as calcium channel antagonists
WO1995011238A1 (en) Heterocyclic amines for treating ischaemic strokes
WO1992022527A2 (en) 3-substituted pyrrolidine derivatives as calcium channel antagonists
US4994617A (en) Aminoalcohols, their preparation process and their applications, particularly in therapeutics
IL98479A (en) Hexahydroazepine derivatives their preparation and pharmaceutical compositions containing them
EP0724578A1 (en) Amine derivatives as calcium channel antagonists
EP0763022A1 (en) Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
WO1995024390A1 (en) Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
AU3959893A (en) N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists
EP0230020B1 (en) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
EP0034647B1 (en) 4-aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments
GB2040936A (en) Phenylthiophenylpiperidines
US5561152A (en) Antidepressants
GB1588469A (en) 1-substituted-3-w-aminoalkoxy)pyrrolidines
WO1995033722A1 (en) Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and tiomorpholines as calcium channel antagonists
US4183933A (en) Diarylbutyl octahydropyrazinopyrimidinones and methods of medical treatment using them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 628725

Date of ref document: 19960416

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1994929558

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994929558

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1994929558

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA